ALDX - Aldeyra Therapeutics Inc.

-

$undefined

N/A

(N/A)

Aldeyra Therapeutics Inc. NASDAQ:ALDX Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer.

Location: | Website: www.aldeyra.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

252.6M

Cash

80.33M

Avg Qtr Burn

-7.68M

Short % of Float

6.91%

Insider Ownership

2.45%

Institutional Own.

60.20%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Reproxalap Details
Dry eye syndrome

NDA

Acceptance for review

ADX-2191 (methotrexate injection (DHFR inhibitor)) Details
Eye disease , Proliferative vitreoretinopathy, Rare diseases, Primary Vitreoretinal Lymphoma

NDA

FDA meeting

Reproxalap (ADX-102) Details
Rare genetic disease, Rare diseases, Allergic conjunctivitis

Phase 3

Update

Phase 2/3

Initiation

ADX-629 Details
Sjögren-Larsson Syndrome

Phase 2

Data readout

ADX-629 Details
Alcoholic hepatitis, Liver disease

Phase 2

Data readout

ADX-629 Details
Chronic cough

Phase 2

Update

ADX-629 Details
Idiopathic Nephrotic Syndrome

Phase 2a

Data readout

ADX-629 Details
Atopic dermatitis

Phase 2a

Update

ADX-246 Details
Atopic dermatitis, Skin disease/disorder

Phase 1/2

Data readout

ADX-248 Details
Age-related macular degeneration, Geographic atrophy

Phase 1/2

Initiation

ADX-248 Details
Atopic dermatitis, Skin disease/disorder

Phase 1

Initiation